The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

An investigational drug from Veru helped preserve lean mass in patients taking Wegovy, though some experts raised questions ...

Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 ...

Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price ...

Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable. In the Phase ...

U.S. Health and Human Services Secretary Xavier Becerra says “this is a big deal.” Drug companies oppose the program.

The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027 ...

A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter ...

Popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of medications ... “Some folks have to ...

Novo Nordisk said that patients taking a higher dose of its blockbuster Wegovy obesity shot lost more weight than those on a lower dose without experiencing an increase in side-effects, according to a ...

The Biden administration moved Friday to negotiate the prices Medicare pays for the blockbuster weight-loss drugs Ozempic and ...